According to the website of the National Medical Products Administration, the 2024 National Conference on Drug Registration Management and Post Market Supervision was held in Chengdu from March 26th to 27th. The meeting pointed out that in 2023, drug regulatory departments at all levels will continue to deepen the reform of the drug evaluation and approval system, and the creation of new drugs will reach a new high; Strengthen post market supervision of drugs and maintain the bottom line of preventing major drug safety incidents from occurring; Strengthen the capacity building of the regulatory system, promote the scientific, legal, international, and modern work of drug supervision. The meeting emphasized that the current structure of drug research and development, production, and operation in China is undergoing a historic restructuring, and the model of drug safety risk governance is undergoing a historic transformation. Drug regulation is facing new opportunities and challenges. We must conscientiously implement the "four strictest" requirements, deeply understand the new situation and challenges we are facing, and fight the "three major battles": first, comprehensively strengthen daily supervision, comprehensively consolidate the responsibilities of all parties, carry out actions to consolidate and improve drug safety, do a good job in post market drug risk monitoring, and fight the "battle" to prevent and resolve drug safety risks; The second is to optimize the review and approval mechanism for innovative drugs, accelerate the speed of new and good drugs going public, improve the quality of government services, and fight a tough battle to accelerate the development of pharmaceutical new quality productivity; The third is to strengthen the capacity building of professional institutions, continuously improve the level of intelligent supervision, gather the collaborative force of national supervision, and win a comprehensive battle to enhance regulatory capabilities. (Lai Xin She)